Misplaced Pages

Oxiperomide

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Oxiperomide
Skeletal formula of oxiperomide
Clinical data
Routes of
administration		Oral
Identifiers
IUPAC name
  • 3--1H-benzimidazol-2-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H23N3O2
Molar mass337.423 g·mol
3D model (JSmol)
SMILES
  • C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCOC4=CC=CC=C4
InChI
  • InChI=1S/C20H23N3O2/c24-20-21-18-8-4-5-9-19(18)23(20)16-10-12-22(13-11-16)14-15-25-17-6-2-1-3-7-17/h1-9,16H,10-15H2,(H,21,24)
  • Key:NVDBBGBUTKLRSN-UHFFFAOYSA-N

Oxiperomide is an antipsychotic. Clinical trials demonstrated that it can reduce dyskinesia in patients with Parkinson's disease who are taking dopamine agonists without increasing Parkinsonian symptoms. It does this by selectively antagonizing dopamine receptors. Further development of this drug is not available. It appears to have never been marketed.

See also

References

  1. Elks J (1990). "Oxiperomide". The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Dordrecht: Springer. ISBN 978-1-4757-2085-3.
  2. Bédard P, Parkes JD, Marsden CD (April 1978). "Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias". British Medical Journal. 1 (6118): 954–956. doi:10.1136/bmj.1.6118.954. PMC 1603806. PMID 638546.
  3. Casey DE, Gerlach J (March 1980). "Oxiperomide in tardive dyskinesia". Journal of Neurology, Neurosurgery, and Psychiatry. 43 (3): 264–267. doi:10.1136/jnnp.43.3.264. PMC 490519. PMID 7373324.
Categories: